- Imricor Medical Systems (IMR) has performed its first procedures using its products at the Heart Centre Dresden in Germany
- Just last week the company received CE mark for its products
- Three procedures were successfully performed over two days using the Vision-MR Ablation Catheter
- CEO Steve Wedan says “It’s another tremendous milestone for Imricor”
- On market close Imricor is down slightly, trading at $1.43 per share
Imricor Medical Systems (IMR) has performed its first procedures using its products at the Heart Centre Dresden in Germany.
Just last week, the company received its CE mark for Vision-MR Ablation Catheter and Vision-MR Dispersive Electrode.
Three procedures were successfully performed over two days by Dr. Christopher Piorkowski and Dr. Thomas Gaspar, using the Vision-MR Ablation Catheter.
The Vision-MR Ablation Catheter is the company’s prime product which is specifically designed to work under realtime MRI guidance.
It aims to have a higher success rate along with faster and safer treatment compared to conventional procedures using x-ray guided catheters.
These procedures mark the first iCMR (interventional cardiovascular magnetic resonance) ablations anywhere in the world to ever be performed outside of a clinical trial.
“It’s another tremendous milestone for Imricor,” said CEO Steve Wedan.
“It marks the beginning of routine clinical use and the coming of age for this exciting new field of iCMR,” he added.
Over the past few months, the company has been working on developing a new imaging technique in the iCMR Design Centre. The technique is called Active Catheter Imaging.
The Active Catheter Imaging uses MR (magnetic resonance) imaging to easily identify the Vision-MR Ablation Catheter, without the use of active tracking or a mapping system.
The product proved to be highly effective in the procedures in Germany. Christopher commented during the procedure, “This is beautiful. It is better than fluoroscopy. In fluoroscopy, you can only imagine the anatomy. Here you see it.”
“Active Catheter Imaging is an exciting technique. It opens the door for more sites to start performing atrial flutter ablations guided by real-time MRI, without a
dependency on mapping system software or active tracking,” Steve told the market.
“This will help support our iCMR lab adoption plans and timelines, and we will continue to lead the development of this new field through continued innovation,” he said.
On market close Imricor is down slightly, trading at $1.43 per share.